157 related articles for article (PubMed ID: 38057786)
21. Liraglutide Decreases Liver Fat Content and Serum Fibroblast Growth Factor 21 Levels in Newly Diagnosed Overweight Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease.
Li X; Wu X; Jia Y; Fu J; Zhang L; Jiang T; Liu J; Wang G
J Diabetes Res; 2021; 2021():3715026. PubMed ID: 34660809
[TBL] [Abstract][Full Text] [Related]
22. Exenatide treatment decreases fasting fibroblast growth factor 21 levels in patients with newly diagnosed type 2 diabetes mellitus.
Hu Y; Liu J; Zhang H; Xu Y; Hong T; Wang G
Diabetes Metab; 2016 Nov; 42(5):358-363. PubMed ID: 27178737
[TBL] [Abstract][Full Text] [Related]
23. Serum Fibroblast Growth Factor 21 Levels Are Positively Associated with Metabolic Syndrome in Patients with Type 2 Diabetes.
Gao RY; Hsu BG; Wu DA; Hou JS; Chen MC
Int J Endocrinol; 2019; 2019():5163245. PubMed ID: 31582974
[TBL] [Abstract][Full Text] [Related]
24. Circulating fibroblast growth factor 21 levels predict progressive kidney disease in subjects with type 2 diabetes and normoalbuminuria.
Lee CH; Hui EY; Woo YC; Yeung CY; Chow WS; Yuen MM; Fong CH; Xu A; Lam KS
J Clin Endocrinol Metab; 2015 Apr; 100(4):1368-75. PubMed ID: 25625802
[TBL] [Abstract][Full Text] [Related]
25. Association of serum fibroblast growth factor 21 with diabetic complications and insulin dose in patients with type 1 diabetes mellitus.
Taniguchi H; Nirengi S; Ishihara K; Sakane N
PLoS One; 2022; 17(2):e0263774. PubMed ID: 35192641
[TBL] [Abstract][Full Text] [Related]
26. Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity.
Mraz M; Bartlova M; Lacinova Z; Michalsky D; Kasalicky M; Haluzikova D; Matoulek M; Dostalova I; Humenanska V; Haluzik M
Clin Endocrinol (Oxf); 2009 Sep; 71(3):369-75. PubMed ID: 19702724
[TBL] [Abstract][Full Text] [Related]
27. Elevated serum fibroblast growth factor 23 levels as an indicator of lower extremity atherosclerotic disease in Chinese patients with type 2 diabetes mellitus.
He X; Hu X; Ma X; Su H; Ying L; Peng J; Pan X; Bao Y; Zhou J; Jia W
Cardiovasc Diabetol; 2017 Jun; 16(1):77. PubMed ID: 28619026
[TBL] [Abstract][Full Text] [Related]
28. Study of the NLRP3 inflammasome component genes and downstream cytokines in patients with type 2 diabetes mellitus with carotid atherosclerosis.
Lee J; Wan J; Lee L; Peng C; Xie H; Lee C
Lipids Health Dis; 2017 Nov; 16(1):217. PubMed ID: 29151018
[TBL] [Abstract][Full Text] [Related]
29. The serum fibroblast growth factor 21 is correlated with retinopathy in patients with type 2 diabetes mellitus.
Heidari Z; Hasanpour M
Diabetes Metab Syndr; 2021; 15(6):102296. PubMed ID: 34592531
[TBL] [Abstract][Full Text] [Related]
30. Circulating levels of fibroblast growth factor 21 in early-stage diabetic kidney disease.
Esteghamati A; Khandan A; Momeni A; Behdadnia A; Ghajar A; Nikdad MS; Noshad S; Nakhjavani M; Afarideh M
Ir J Med Sci; 2017 Aug; 186(3):785-794. PubMed ID: 28181108
[TBL] [Abstract][Full Text] [Related]
31. Daily physical activity, fasting glucose, uric acid, and body mass index are independent factors associated with serum fibroblast growth factor 21 levels.
Cuevas-Ramos D; Almeda-Valdes P; Gómez-Pérez FJ; Meza-Arana CE; Cruz-Bautista I; Arellano-Campos O; Navarrete-López M; Aguilar-Salinas CA
Eur J Endocrinol; 2010 Sep; 163(3):469-77. PubMed ID: 20566587
[TBL] [Abstract][Full Text] [Related]
32. Association between serum haptoglobin and carotid arterial functions: usefulness of a targeted metabolomics approach.
Wang S; Wang J; Zhang R; Zhao A; Zheng X; Yan D; Jiang F; Jia W; Hu C; Jia W
Cardiovasc Diabetol; 2019 Jan; 18(1):8. PubMed ID: 30634984
[TBL] [Abstract][Full Text] [Related]
33. Association of elevated circulating fibroblast growth factor 21 levels with prevalent and incident metabolic syndrome: The Multi-Ethnic Study of Atherosclerosis.
Ong KL; McClelland RL; Allison MA; Kokkinos J; Wu BJ; Barter PJ; Rye KA
Atherosclerosis; 2019 Feb; 281():200-206. PubMed ID: 30446181
[TBL] [Abstract][Full Text] [Related]
34. The relationship between serum levels of fibroblast growth factor 21 and diabetic retinopathy.
Mousavi Z; Bonakdaran S; Sahebkar A; Yaghoubi G; Yaghoubi MA; Davoudian N; Mohebbi M
EXCLI J; 2017; 16():1249-1256. PubMed ID: 29285020
[TBL] [Abstract][Full Text] [Related]
35. The potential effect of metformin on fibroblast growth factor 21 in type 2 diabetes mellitus (T2DM).
Al-Kuraishy HM; Al-Gareeb AI; Saad HM; Batiha GE
Inflammopharmacology; 2023 Aug; 31(4):1751-1760. PubMed ID: 37337094
[TBL] [Abstract][Full Text] [Related]
36. Association between serum fibroblast growth factor 21 level and sight-threatening diabetic retinopathy in Chinese patients with type 2 diabetes.
Jin S; Xia N; Han L
BMJ Open Diabetes Res Care; 2021 Mar; 9(1):. PubMed ID: 33789910
[TBL] [Abstract][Full Text] [Related]
37. Additive relationship between serum fibroblast growth factor 21 level and coronary artery disease.
Shen Y; Ma X; Zhou J; Pan X; Hao Y; Zhou M; Lu Z; Gao M; Bao Y; Jia W
Cardiovasc Diabetol; 2013 Aug; 12():124. PubMed ID: 23981342
[TBL] [Abstract][Full Text] [Related]
38. Dynamic change of serum FGF21 levels in response to glucose challenge in human.
Lin Z; Gong Q; Wu C; Yu J; Lu T; Pan X; Lin S; Li X
J Clin Endocrinol Metab; 2012 Jul; 97(7):E1224-8. PubMed ID: 22539584
[TBL] [Abstract][Full Text] [Related]
39. Serum fibroblast growth factor 21 is a superior biomarker to other adipokines in predicting incident diabetes.
Woo YC; Lee CH; Fong CH; Xu A; Tso AW; Cheung BM; Lam KS
Clin Endocrinol (Oxf); 2017 Jan; 86(1):37-43. PubMed ID: 27611701
[TBL] [Abstract][Full Text] [Related]
40. Association of Hepatic Steatosis Index and Fatty Liver Index with Carotid Atherosclerosis in Type 2 Diabetes.
Wang C; Cai Z; Deng X; Li H; Zhao Z; Guo C; Zhang P; Li L; Gu T; Yang L; Zhao L; Wang D; Yuan G
Int J Med Sci; 2021; 18(14):3280-3289. PubMed ID: 34400897
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
